

# Lipika Goyal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7074516/publications.pdf>

Version: 2024-02-01

131  
papers

7,793  
citations

87843

38  
h-index

56687

83  
g-index

135  
all docs

135  
docs citations

135  
times ranked

8905  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , 2020, 21, 796-807.	5.1	620
2	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
3	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	2.3	477
4	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2018, 4, 963.	3.4	426
5	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962.	7.7	419
6	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	7.7	384
7	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	0.8	363
8	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	15.2	359
9	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	3.4	353
10	Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2310-2318.	3.2	276
11	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	7.7	254
12	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205
13	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	3.4	194
14	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
15	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	3.7	161
16	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1123-1128.	3.3	133
17	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016, 6, 727-739.	7.7	126
18	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415.	7.7	119

#	ARTICLE	IF	CITATIONS
19	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
20	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	5.7	112
21	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.4	99
22	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. <i>Cancer</i> , 2017, 123, 1979-1988.	2.0	92
23	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
24	Targeting FGFR inhibition in cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2021, 95, 102170.	3.4	85
25	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	82
26	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. <i>Annals of Surgical Oncology</i> , 2016, 23, 290-296.	0.7	80
27	Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.. <i>Journal of Clinical Oncology</i> , 2021, 39, 265-265.	0.8	70
28	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444.	1.2	69
29	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
30	Safety and Efficacy of 70µm and 100µm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 516-522.	0.2	62
31	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 80-89.	3.2	62
32	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	1.1	62
33	FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> gene fusions or other rearrangements.. <i>Journal of Clinical Oncology</i> , 2020, 38, 108-108.	0.8	61
34	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	56
35	Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immuno-evasion and Tumor Maintenance in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 812-835.	7.7	55
36	<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 2488-2505.	7.7	46

#	ARTICLE	IF	CITATIONS
37	Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1799-1802.	0.9	45
38	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
39	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. Journal of Clinical Oncology, 2019, 37, 4087-4087.	0.8	42
40	A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 128-137.	1.2	40
41	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clinical Cancer Research, 2020, 26, 6158-6167.	3.2	37
42	Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nature Communications, 2021, 12, 3199.	5.8	33
43	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 2022, 12, 1378-1395.	7.7	33
44	Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.. Journal of Clinical Oncology, 2022, 40, 4009-4009.	0.8	33
45	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1871-1884.	3.3	32
46	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, 26, e1036-e1049.	1.9	30
47	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 123-132.	1.5	30
48	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discovery, 2022, 12, 1462-1481.	7.7	30
49	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 1122-1129.	0.7	29
50	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. Cancer Research, 2021, 81, CT010-CT010.	0.4	28
51	Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. Journal of Clinical Oncology, 2020, 38, 3603-3603.	0.8	23
52	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	1.3	21
53	FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.. Journal of Clinical Oncology, 2019, 37, TPS3157-TPS3157.	0.8	18
54	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421.	1.1	17

#	ARTICLE	IF	CITATIONS
55	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020, 16, 1069-1081.	1.1	15
56	FOLFOX plus zivâ€flibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221.	2.0	14
57	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2020, 73, 23-29.	1.0	14
58	Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. <i>Future Oncology</i> , 2021, 17, 2057-2074.	1.1	14
59	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 1533-1539.	1.2	13
60	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	0.5	13
61	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 386-386.	0.8	13
62	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 953-959.	0.9	12
63	First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4165-TPS4165.	0.8	11
64	A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 547-547.	0.8	10
65	Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab. <i>Kidney International Reports</i> , 2021, 6, 1464-1468.	0.4	9
66	A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 800-800.	0.8	9
67	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4116-4116.	0.8	9
68	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 248-260.	1.8	8
69	Associations of baseline patientâ€reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	2.0	7
70	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 161-173.	1.8	7
71	Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15674-e15674.	0.8	7
72	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 272-272.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. <i>Cancer</i> , 2020, 126, 3569-3578.	2.0	6
74	Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 237-237.	0.8	6
75	Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15603-e15603.	0.8	6
76	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring <i>FGFR2</i> gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS468-TPS468.	0.8	6
77	PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an <i>FGFR2</i> gene fusion/rearrangement.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4171-TPS4171.	0.8	6
78	Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4084-4084.	0.8	5
79	A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4591-4591.	0.8	5
80	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
81	Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. <i>Chinese Clinical Oncology</i> , 2020, 9, 7-7.	0.4	4
82	FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with <i>FGFR2</i> fusions/rearrangements.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4097-4097.	0.8	4
83	Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 693-693.	0.8	4
84	Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 567-576.	2.3	4
85	Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS351-TPS351.	0.8	3
86	A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS358-TPS358.	0.8	3
87	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4128-4128.	0.8	3
88	Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 348-348.	0.8	3
89	A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16643-e16643.	0.8	3
90	Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 515-515.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Chemotherapy and antiangiogenics in biliary tract cancer. <i>Lancet Oncology</i> , The, 2015, 16, 882-883.	5.1	2
92	Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. <i>JAMA Oncology</i> , 2019, 5, 938.	3.4	2
93	The Tipping Point: Key Oncologic Imaging Findings Resulting in Critical Changes in the Management of Malignant Tumors of the Gastrointestinal Tract. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 61-74.	0.6	2
94	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187.	1.1	2
95	Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1054-1064.	13.9	2
96	Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 562-562.	0.8	2
97	Combining systemic and local therapies for hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 976-978.	3.7	2
98	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019, 37, 392-392.	0.8	2
99	Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3563-3563.	0.8	2
100	NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS602-TPS602.	0.8	2
101	Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 149-149.	0.8	2
102	Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15611-e15611.	0.8	1
103	Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4164-TPS4164.	0.8	1
104	P024â€...KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. , 2021, , .		1
105	A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2543-2543.	0.8	1
106	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and RO resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 368-368.	0.8	1
107	Changes in alpha-fetoprotein (AFP) and systemic therapy outcomes in advanced hepatocellular carcinoma (HCC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 346-346.	0.8	1
108	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 412-412.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 567-567.	0.8	1
110	A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 259-259.	0.8	1
111	External beam radiotherapy for hepatocellular carcinoma with right atrium tumor thrombus.. Journal of Clinical Oncology, 2019, 37, 328-328.	0.8	1
112	Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.. Journal of Clinical Oncology, 2020, 38, 579-579.	0.8	1
113	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2022, 40, TPS485-TPS485.	0.8	1
114	Bridging the Gap Between Sorafenib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist, 2016, 21, 1283-1285.	1.9	0
115	Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 564-572.	0.6	0
116	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2021, 39, 6560-6560.	0.8	0
117	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.. Journal of Clinical Oncology, 2021, 39, e16253-e16253.	0.8	0
118	Paving a pathway for drug development in HER2-positive biliary tract cancer. Lancet Oncology, The, 2021, 22, 1204-1206.	5.1	0
119	Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2021, 39, 154-154.	0.8	0
120	A phase I study of ADENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 260-260.	0.8	0
121	Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).. Journal of Clinical Oncology, 2014, 32, 9639-9639.	0.8	0
122	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, TPS4157-TPS4157.	0.8	0
123	Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for local advanced gastric or Siewert II/III GEJ cancer: A retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 115-115.	0.8	0
124	Frequency and feasibility of detecting FGFR mRNA expression in archival samples of patients with cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2019, 37, 281-281.	0.8	0
125	Patterns of care and outcomes of definitive external beam radiotherapy and radioembolization for localized hepatocellular carcinoma: A propensity score-adjusted analysis.. Journal of Clinical Oncology, 2019, 37, 329-329.	0.8	0
126	The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2020, 38, 833-833.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Comparing clinicopathologic feature and treatment outcome of patients who underwent surgical resection or liver transplant for nonalcoholic fatty liver disease (NAFLD)-related and non-NAFLD related hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, e16675-e16675.	0.8	0
128	Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 580-580.	0.8	0
129	Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 186-186.	0.8	0
130	Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2022, 40, 6570-6570.	0.8	0
131	Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).. Journal of Clinical Oncology, 2022, 40, TPS9601-TPS9601.	0.8	0